文献速递肾癌与肾肿瘤

立体定向体部放疗治疗原发性肾细胞癌:大型多中心系列研究结果

Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series.
PubMed 文献 · Eur Urol Oncol · 2025-02-07

这项多中心回顾性研究纳入澳大利亚、法国、意大利和荷兰16个中心的144例原发性肾细胞癌患者,2008年至2020年接受立体定向体部放疗(SBRT),中位随访43个月。1年局部控制概率为98%(95%CI 94-99),5年为96%(95%CI 92-99);5年癌症相关死亡累积发生率为8%(95%CI 3-15);49%患者出现至少1种毒性,3级为1%,2例(1%)需透析(4级);末次随访中位eGFR下降-7 ml/min。SBRT是不可手术患者的替代治疗选择。

要点

  • SBRT治疗原发性肾细胞癌的5年局部控制概率为96%(95%CI 92-99)。
  • 49%患者出现至少1种毒性,3级毒性1%,2例(1%)需透析(4级)。
  • 末次随访中位eGFR下降-7 ml/min(IQR -17;0)。

核心结论

  • 该大型系列显示SBRT治疗原发性肾细胞癌具有优异的局部控制和肾功能保护,毒性谱可接受,是不可手术患者的替代治疗选择。

研究设计与样本

  • 多中心回顾性研究,涉及澳大利亚、法国、意大利和荷兰的16个中心,纳入2008年至2020年间治疗的144例原发性肾细胞癌患者,中位随访43个月(IQR 24.0-81.2)。

主要发现

  • 1年局部控制概率为98%(95%CI 94-99),5年为96%(95%CI 92-99)。
  • 中位总生存期为58个月,5年癌症相关死亡累积发生率为8%(95%CI 3-15)。
  • 71例患者(49%)出现至少1种毒性,其中1级占多数(32%),2级14%,3级1%;2例(1%)接受透析(4级)。
  • 末次随访中位eGFR下降-7 ml/min(IQR -17;0)。

关键数值与推荐

  • 中位年龄76岁(IQR 67.0-82.0),中位肿瘤大小4.4 cm(IQR 3.3-5.6)。
  • 中位基线eGFR为60 ml/min/1.73 m2,40%患者eGFR为30-60 ml/min(轻至中度下降)。
  • 两种主要治疗方案为42 Gy分3次和26 Gy分1次。

临床怎么用

  • SBRT是不可手术原发性肾细胞癌患者的替代治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: For inoperable patients, stereotactic body radiation therapy (SBRT) is a noninvasive treatment approach for primary renal cell carcinoma (RCC). We aimed to evaluate local control (LC) of primary RCC treated with SBRT. METHODS: This multicenter retrospective study involved 16 centers in Australia, France, Italy, and the Netherlands. The primary endpoint was the LC probability, and the secondary endpoints were progression-free survival, overall survival (OS), cumulative incidence of cancer-related deaths, toxicities, and renal function evolution after SBRT. KEY FINDINGS AND LIMITATIONS: A total of 144 patients, treated between 2008 and 2020, with a median follow-up of 43 mo (interquartile range [IQR], 24.0-81.2), were included. The median age was 76 yr (IQR, 67.0-82.0) and the median tumor size was 4.4 cm (IQR, 3.3-5.6). The median baseline estimated glomerular filtration rate (eGFR) was 60 ml/min/1.73 m2. Of the patients, 40% had mild to moderate eGFR (30-60 ml/min). The two main treatment regimens were 42 Gy in three fractions and 26 Gy in one fraction. The LC probability was 98% at 1 yr (95% confidence interval [CI], 94-99) and 96% (95% CI, 92-99) at 5 yr. The median OS was 58 mo and the cumulative incidence of cancer-related deaths was 8% (95% CI, 3-15) at 5 yr. Seventy-one patients (49%) experienced at least one toxicity, including grade 1 in the majority (32%), grade 2 (14%), and grade 3 (1%). Two patients (1%) underwent dialysis (grade 4). The median eGFR loss was -7 ml/min (IQR, -17; 0) at the last follow-up. CONCLUSIONS AND CLINICAL IMPLICATIONS: This large series of primary RCC treated with SBRT demonstrates excellent LC and renal function preservation, and is associated with an acceptable toxicity profile. SBRT is an alternative treatment for inoperable patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Abancourt L, Ali M, Quivrin M, et al. Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series. Eur Urol Oncol. 2025. PMID: 39920013. doi:10.1016/j.euo.2025.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。